Global Cancer Antibody Drug Conjugates research

Cancer Antibody Drug Conjugates Comprehensive Study by Type (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others), Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others), Distribution Channel (Hospital, Clinics, Others) Players and Region - Global Market Outlook to 2026

Cancer Antibody Drug Conjugates Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
The Global Cancer Antibody Drug Conjugates market presents a comprehensive analysis of the Cancer Antibody Drug Conjugates market by product type (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up.

Market Snapshot:
Antibody drug conjugates are medications that are meant to target certain cancer cells while also releasing a harmful substance into them. Obesity, smoking, drinking, and poor dietary habits are all major causes of cancer. The increased cell-killing power of monoclonal antibodies, improved tumour selectivity, increased drug tolerance, and less systemic exposure are all advantages of ADCs.

Market Drivers
  • Increasing geriatric population

Market Trend
  • Developing new technology of cancer antibody drugs conjugate

Restraints
  • Manufacturing cost is high of antibody-drug conjugates


Geographic Segmentation and Analysis
This section of our report presents a realistic picture of the Global Cancer Antibody Drug Conjugates industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Report Objectives / Segmentation Covered

By Type
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Others
By Technology
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology
  • Others

By Distribution Channel
  • Hospital
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Required trained operators
    • 3.4. Market Trends
      • 3.4.1. Developing new technology of cancer antibody drugs conjugate
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Antibody Drug Conjugates, by Type, Technology, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cancer Antibody Drug Conjugates (Value)
      • 5.2.1. Global Cancer Antibody Drug Conjugates by: Type (Value)
        • 5.2.1.1. Blood Cancer
        • 5.2.1.2. Breast Cancer
        • 5.2.1.3. Ovarian Cancer
        • 5.2.1.4. Lung Cancer
        • 5.2.1.5. Brain Tumor
        • 5.2.1.6. Others
      • 5.2.2. Global Cancer Antibody Drug Conjugates by: Technology (Value)
        • 5.2.2.1. Immunogen Technology
        • 5.2.2.2. Seattle Genetics Technology
        • 5.2.2.3. Immunomedics Technology
        • 5.2.2.4. Others
      • 5.2.3. Global Cancer Antibody Drug Conjugates by: Distribution Channel (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Cancer Antibody Drug Conjugates Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Cancer Antibody Drug Conjugates: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma/Agensys (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Oxford BioTherapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Antikor (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celldex Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Heidelberg Pharma (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Immunomedics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mersana Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Millennium Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Progenics Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Antibody Drug Conjugates Sale, by Type, Technology, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cancer Antibody Drug Conjugates (Value)
      • 7.2.1. Global Cancer Antibody Drug Conjugates by: Type (Value)
        • 7.2.1.1. Blood Cancer
        • 7.2.1.2. Breast Cancer
        • 7.2.1.3. Ovarian Cancer
        • 7.2.1.4. Lung Cancer
        • 7.2.1.5. Brain Tumor
        • 7.2.1.6. Others
      • 7.2.2. Global Cancer Antibody Drug Conjugates by: Technology (Value)
        • 7.2.2.1. Immunogen Technology
        • 7.2.2.2. Seattle Genetics Technology
        • 7.2.2.3. Immunomedics Technology
        • 7.2.2.4. Others
      • 7.2.3. Global Cancer Antibody Drug Conjugates by: Distribution Channel (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Cancer Antibody Drug Conjugates Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Antibody Drug Conjugates: by Type(USD Million)
  • Table 2. Cancer Antibody Drug Conjugates Blood Cancer , by Region USD Million (2015-2020)
  • Table 3. Cancer Antibody Drug Conjugates Breast Cancer , by Region USD Million (2015-2020)
  • Table 4. Cancer Antibody Drug Conjugates Ovarian Cancer , by Region USD Million (2015-2020)
  • Table 5. Cancer Antibody Drug Conjugates Lung Cancer , by Region USD Million (2015-2020)
  • Table 6. Cancer Antibody Drug Conjugates Brain Tumor , by Region USD Million (2015-2020)
  • Table 7. Cancer Antibody Drug Conjugates Others , by Region USD Million (2015-2020)
  • Table 8. Cancer Antibody Drug Conjugates: by Technology(USD Million)
  • Table 9. Cancer Antibody Drug Conjugates Immunogen Technology , by Region USD Million (2015-2020)
  • Table 10. Cancer Antibody Drug Conjugates Seattle Genetics Technology , by Region USD Million (2015-2020)
  • Table 11. Cancer Antibody Drug Conjugates Immunomedics Technology , by Region USD Million (2015-2020)
  • Table 12. Cancer Antibody Drug Conjugates Others , by Region USD Million (2015-2020)
  • Table 13. Cancer Antibody Drug Conjugates: by Distribution Channel(USD Million)
  • Table 14. Cancer Antibody Drug Conjugates Hospital , by Region USD Million (2015-2020)
  • Table 15. Cancer Antibody Drug Conjugates Clinics , by Region USD Million (2015-2020)
  • Table 16. Cancer Antibody Drug Conjugates Others , by Region USD Million (2015-2020)
  • Table 17. South America Cancer Antibody Drug Conjugates, by Country USD Million (2015-2020)
  • Table 18. South America Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 19. South America Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 20. South America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 22. Brazil Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 23. Brazil Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 24. Argentina Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 25. Argentina Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 26. Argentina Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 27. Rest of South America Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 29. Rest of South America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Cancer Antibody Drug Conjugates, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 33. Asia Pacific Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 34. China Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 35. China Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 36. China Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 37. Japan Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 38. Japan Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 39. Japan Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 40. India Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 41. India Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 42. India Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 43. South Korea Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 44. South Korea Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 45. South Korea Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 46. Taiwan Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 47. Taiwan Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 48. Taiwan Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 49. Australia Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 50. Australia Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 51. Australia Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Cancer Antibody Drug Conjugates, by Country USD Million (2015-2020)
  • Table 56. Europe Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 57. Europe Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 58. Europe Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 59. Germany Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 60. Germany Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 61. Germany Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 62. France Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 63. France Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 64. France Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 65. Italy Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 66. Italy Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 67. Italy Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 68. United Kingdom Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 70. United Kingdom Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 71. Netherlands Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 72. Netherlands Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 73. Netherlands Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 74. Rest of Europe Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 76. Rest of Europe Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Cancer Antibody Drug Conjugates, by Country USD Million (2015-2020)
  • Table 78. MEA Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 79. MEA Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 80. MEA Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 81. Middle East Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 82. Middle East Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 83. Middle East Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 84. Africa Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 85. Africa Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 86. Africa Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Cancer Antibody Drug Conjugates, by Country USD Million (2015-2020)
  • Table 88. North America Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 89. North America Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 90. North America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 91. United States Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 92. United States Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 93. United States Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 94. Canada Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 95. Canada Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 96. Canada Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 97. Mexico Cancer Antibody Drug Conjugates, by Type USD Million (2015-2020)
  • Table 98. Mexico Cancer Antibody Drug Conjugates, by Technology USD Million (2015-2020)
  • Table 99. Mexico Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Cancer Antibody Drug Conjugates: by Type(USD Million)
  • Table 111. Cancer Antibody Drug Conjugates Blood Cancer , by Region USD Million (2021-2026)
  • Table 112. Cancer Antibody Drug Conjugates Breast Cancer , by Region USD Million (2021-2026)
  • Table 113. Cancer Antibody Drug Conjugates Ovarian Cancer , by Region USD Million (2021-2026)
  • Table 114. Cancer Antibody Drug Conjugates Lung Cancer , by Region USD Million (2021-2026)
  • Table 115. Cancer Antibody Drug Conjugates Brain Tumor , by Region USD Million (2021-2026)
  • Table 116. Cancer Antibody Drug Conjugates Others , by Region USD Million (2021-2026)
  • Table 117. Cancer Antibody Drug Conjugates: by Technology(USD Million)
  • Table 118. Cancer Antibody Drug Conjugates Immunogen Technology , by Region USD Million (2021-2026)
  • Table 119. Cancer Antibody Drug Conjugates Seattle Genetics Technology , by Region USD Million (2021-2026)
  • Table 120. Cancer Antibody Drug Conjugates Immunomedics Technology , by Region USD Million (2021-2026)
  • Table 121. Cancer Antibody Drug Conjugates Others , by Region USD Million (2021-2026)
  • Table 122. Cancer Antibody Drug Conjugates: by Distribution Channel(USD Million)
  • Table 123. Cancer Antibody Drug Conjugates Hospital , by Region USD Million (2021-2026)
  • Table 124. Cancer Antibody Drug Conjugates Clinics , by Region USD Million (2021-2026)
  • Table 125. Cancer Antibody Drug Conjugates Others , by Region USD Million (2021-2026)
  • Table 126. South America Cancer Antibody Drug Conjugates, by Country USD Million (2021-2026)
  • Table 127. South America Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 128. South America Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 129. South America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 130. Brazil Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 131. Brazil Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 132. Brazil Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 133. Argentina Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 134. Argentina Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 135. Argentina Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 136. Rest of South America Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 137. Rest of South America Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 138. Rest of South America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 139. Asia Pacific Cancer Antibody Drug Conjugates, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 142. Asia Pacific Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 143. China Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 144. China Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 145. China Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 146. Japan Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 147. Japan Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 148. Japan Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 149. India Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 150. India Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 151. India Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 152. South Korea Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 153. South Korea Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 154. South Korea Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 155. Taiwan Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 156. Taiwan Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 157. Taiwan Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 158. Australia Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 159. Australia Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 160. Australia Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 164. Europe Cancer Antibody Drug Conjugates, by Country USD Million (2021-2026)
  • Table 165. Europe Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 166. Europe Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 167. Europe Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 168. Germany Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 169. Germany Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 170. Germany Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 171. France Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 172. France Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 173. France Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 174. Italy Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 175. Italy Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 176. Italy Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 177. United Kingdom Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 178. United Kingdom Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 179. United Kingdom Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 180. Netherlands Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 181. Netherlands Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 182. Netherlands Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 183. Rest of Europe Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 185. Rest of Europe Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 186. MEA Cancer Antibody Drug Conjugates, by Country USD Million (2021-2026)
  • Table 187. MEA Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 188. MEA Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 189. MEA Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 190. Middle East Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 191. Middle East Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 192. Middle East Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 193. Africa Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 194. Africa Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 195. Africa Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 196. North America Cancer Antibody Drug Conjugates, by Country USD Million (2021-2026)
  • Table 197. North America Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 198. North America Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 199. North America Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 200. United States Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 201. United States Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 202. United States Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 203. Canada Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 204. Canada Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 205. Canada Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 206. Mexico Cancer Antibody Drug Conjugates, by Type USD Million (2021-2026)
  • Table 207. Mexico Cancer Antibody Drug Conjugates, by Technology USD Million (2021-2026)
  • Table 208. Mexico Cancer Antibody Drug Conjugates, by Distribution Channel USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Antibody Drug Conjugates: by Type USD Million (2015-2020)
  • Figure 5. Global Cancer Antibody Drug Conjugates: by Technology USD Million (2015-2020)
  • Figure 6. Global Cancer Antibody Drug Conjugates: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 8. Asia Pacific Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 9. Europe Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 10. MEA Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 11. North America Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 12. Global Cancer Antibody Drug Conjugates share by Players 2020 (%)
  • Figure 13. Global Cancer Antibody Drug Conjugates share by Players (Top 3) 2020(%)
  • Figure 14. Global Cancer Antibody Drug Conjugates share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Astellas Pharma/Agensys (United States) Revenue, Net Income and Gross profit
  • Figure 17. Astellas Pharma/Agensys (United States) Revenue: by Geography 2020
  • Figure 18. Oxford BioTherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Oxford BioTherapeutics (United States) Revenue: by Geography 2020
  • Figure 20. Antikor (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Antikor (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Celldex Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Celldex Therapeutics (United States) Revenue: by Geography 2020
  • Figure 24. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 25. Genentech (United States) Revenue: by Geography 2020
  • Figure 26. Heidelberg Pharma (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Heidelberg Pharma (Germany) Revenue: by Geography 2020
  • Figure 28. Immunomedics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Immunomedics (United States) Revenue: by Geography 2020
  • Figure 30. Mersana Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Mersana Therapeutics (United States) Revenue: by Geography 2020
  • Figure 32. Millennium Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Millennium Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 34. Progenics Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 35. Progenics Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 36. Global Cancer Antibody Drug Conjugates: by Type USD Million (2021-2026)
  • Figure 37. Global Cancer Antibody Drug Conjugates: by Technology USD Million (2021-2026)
  • Figure 38. Global Cancer Antibody Drug Conjugates: by Distribution Channel USD Million (2021-2026)
  • Figure 39. South America Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 40. Asia Pacific Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 41. Europe Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 42. MEA Cancer Antibody Drug Conjugates Share (%), by Country
  • Figure 43. North America Cancer Antibody Drug Conjugates Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Astellas Pharma/Agensys (United States)
  • Oxford BioTherapeutics (United States)
  • Antikor (United Kingdom)
  • Celldex Therapeutics (United States)
  • Genentech (United States)
  • Heidelberg Pharma (Germany)
  • Immunomedics (United States)
  • Mersana Therapeutics (United States)
  • Millennium Pharmaceuticals (United States)
  • Progenics Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Roche Holding Ag (Switzerland) , Synthon (Netherlands)
Select User Access Type

Key Highlights of Report


Jan 2022 249 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Antibody Drug Conjugates research Quantitative research analysis
Global Cancer Antibody Drug Conjugates research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.

Know More About Global Cancer Antibody Drug Conjugates research Report?

Have a Query? Click Here

Other Related Reports

Morphine Comprehensive Study by Application (Arthritis, Diarrhea, Pain Relief, Cancer, Others), Forms (Solid, Liquid), Route of Administration (Oral, Parenteral, Intravenous, Others), Distribution Ch...
$ 3800
Allergy Diagnostic Comprehensive Study by Type (Drug Allergens, Inhaled Allergens, Food Allergens, Others), Medications (Antihistamines, Decongestants, Corticosteroids, Others), End-User (Academic R...
$ 3450
Injectable Drug Delivery Comprehensive Study by Type (Devices, Conventional Injection Device {Prefilled Syringes and Fillable Syringes}, Self-injection Devices {Needle-Free Injectors (NFI), Wearable ...
$ 3750
Anthrax Vaccines Comprehensive Study by Type (Live Vaccines, Cell free PA Vaccines), Application (Human Use, Animal Use), Disease Type (Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax...
$ 3450
Fibrin Glue Comprehensive Study by Type (Hemostat, Adhesive, Sealant), Application (Hemostasis, Sealing, Tissue Gluing, Support for Wound Healing, Arein cardiac surgery, Burn to bleed, Pulmonary su...
$ 3450
Lignocaine Comprehensive Study by Application (Local Anesthesia, Dentistry, Cardiac Arrhythmia, Epilepsy, Cosmetics, Anti-Arrhythmic, Others), Formulations (Injections, Creams, Ointments, Gels, Aeros...
$ 3450